Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
121.40
-2.62 (-2.11%)
Nov 20, 2026, 4:00 PM EST - Market closed
Protagonist Therapeutics Employees
Protagonist Therapeutics had 149 employees as of September 30, 2026. The number of employees increased by 21 or 16.41% compared to the same quarter last year. That makes Protagonist Therapeutics the 28,898th largest employer in the world and 3,649th in the United States.
Employees
149
Change (1Y)
21
Growth (1Y)
16.41%
Revenue / Employee
$3,702,617
Profits / Employee
$2,297,067
Market Cap
7.92B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 149 | 21 | 16.41% |
| Jun 30, 2026 | 141 | 11 | 8.46% |
| Mar 31, 2026 | 131 | 7 | 5.65% |
| Dec 31, 2025 | 132 | 6 | 4.76% |
| Sep 30, 2025 | 128 | 2 | 1.59% |
| Jun 30, 2025 | 130 | 5 | 4.00% |
| Mar 31, 2025 | 124 | 0 | - |
| Dec 31, 2024 | 126 | 14 | 12.50% |
| Sep 30, 2024 | 126 | 15 | 13.51% |
| Jun 30, 2024 | 125 | 19 | 17.92% |
| Mar 31, 2024 | 124 | 21 | 20.39% |
| Dec 31, 2023 | 112 | 7 | 6.67% |
| Sep 30, 2023 | 111 | -11 | -9.02% |
| Jun 30, 2023 | 106 | -21 | -16.54% |
| Mar 31, 2023 | 103 | -19 | -15.57% |
| Dec 31, 2022 | 105 | -13 | -11.02% |
| Sep 30, 2022 | 122 | 6 | 5.17% |
| Jun 30, 2022 | 127 | 26 | 25.74% |
| Mar 31, 2022 | 122 | 39 | 46.99% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Axsome Therapeutics | 1,390 |
| Twist Bioscience | 1,080 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Cytokinetics | 673 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Summit Therapeutics | 265 |
PTGX News
- 5 days ago - Protagonist Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 11 days ago - Protagonist Therapeutics Transcript: 8th Annual Wolfe Research Healthcare Conference - Transcripts
- 12 days ago - Protagonist Therapeutics price target raised to $151 from $149 at JPMorgan - TheFly
- 12 days ago - Protagonist Therapeutics Slides: Corporate presentation - Filings
- 16 days ago - Protagonist Therapeutics reports Q3 EPS $3.07, consensus $2.66 - TheFly
- 16 days ago - Protagonist Therapeutics Earnings release: Q3 2026 - Filings
- 16 days ago - Protagonist Therapeutics Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Protagonist Therapeutics price target raised to $160 from $155 at TD Cowen - TheFly